Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More
Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More
DISHMAN PHARMA | PANACEA BIOTECH | DISHMAN PHARMA/ PANACEA BIOTECH |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 25.1 | 8.9 | 282.4% | View Chart |
P/BV | x | 3.3 | 3.5 | 96.7% | View Chart |
Dividend Yield | % | 0.7 | 0.0 | - |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
DISHMAN PHARMA Mar-16 |
PANACEA BIOTECH Mar-19 |
DISHMAN PHARMA/ PANACEA BIOTECH |
5-Yr Chart Click to enlarge
|
||
High | Rs | 374 | 354 | 105.9% | |
Low | Rs | 129 | 138 | 93.3% | |
Sales per share (Unadj.) | Rs | 197.8 | 74.6 | 265.3% | |
Earnings per share (Unadj.) | Rs | 21.2 | 6.7 | 317.5% | |
Cash flow per share (Unadj.) | Rs | 34.7 | 15.5 | 224.1% | |
Dividends per share (Unadj.) | Rs | 2.00 | 0 | - | |
Dividend yield (eoy) | % | 0.8 | 0 | - | |
Book value per share (Unadj.) | Rs | 179.9 | 57.2 | 314.5% | |
Shares outstanding (eoy) | m | 80.69 | 61.25 | 131.7% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 1.3 | 3.3 | 38.6% | |
Avg P/E ratio | x | 11.9 | 36.8 | 32.2% | |
P/CF ratio (eoy) | x | 7.2 | 15.9 | 45.7% | |
Price / Book Value ratio | x | 1.4 | 4.3 | 32.5% | |
Dividend payout | % | 9.4 | 0 | - | |
Avg Mkt Cap | Rs m | 20,306 | 15,061 | 134.8% | |
No. of employees | `000 | 0.8 | 2.3 | 35.8% | |
Total wages/salary | Rs m | 5,355 | 1,471 | 364.1% | |
Avg. sales/employee | Rs Th | 19,252.7 | 1,973.6 | 975.5% | |
Avg. wages/employee | Rs Th | 6,459.5 | 635.6 | 1,016.3% | |
Avg. net profit/employee | Rs Th | 2,064.1 | 176.8 | 1,167.5% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 15,961 | 4,567 | 349.5% | |
Other income | Rs m | 265 | 45 | 592.4% | |
Total revenues | Rs m | 16,226 | 4,612 | 351.8% | |
Gross profit | Rs m | 4,103 | 2,030 | 202.2% | |
Depreciation | Rs m | 1,091 | 540 | 202.0% | |
Interest | Rs m | 944 | 1,048 | 90.1% | |
Profit before tax | Rs m | 2,334 | 486 | 480.0% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 1 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 624 | 77 | 808.8% | |
Profit after tax | Rs m | 1,711 | 409 | 418.3% | |
Gross profit margin | % | 25.7 | 44.4 | 57.8% | |
Effective tax rate | % | 26.7 | 15.9 | 168.5% | |
Net profit margin | % | 10.7 | 9.0 | 119.7% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 11,018 | 2,415 | 456.3% | |
Current liabilities | Rs m | 9,517 | 9,077 | 104.8% | |
Net working cap to sales | % | 9.4 | -145.9 | -6.4% | |
Current ratio | x | 1.2 | 0.3 | 435.2% | |
Inventory Days | Days | 110 | 65 | 169.8% | |
Debtors Days | Days | 35 | 71 | 49.1% | |
Net fixed assets | Rs m | 16,304 | 8,333 | 195.7% | |
Share capital | Rs m | 161 | 61 | 263.3% | |
"Free" reserves | Rs m | 12,907 | 3,443 | 374.9% | |
Net worth | Rs m | 14,516 | 3,504 | 414.3% | |
Long term debt | Rs m | 4,189 | 461 | 908.4% | |
Total assets | Rs m | 29,805 | 13,755 | 216.7% | |
Interest coverage | x | 3.5 | 1.5 | 237.1% | |
Debt to equity ratio | x | 0.3 | 0.1 | 219.3% | |
Sales to assets ratio | x | 0.5 | 0.3 | 161.3% | |
Return on assets | % | 8.9 | 10.6 | 84.1% | |
Return on equity | % | 11.8 | 11.7 | 101.0% | |
Return on capital | % | 17.5 | 38.7 | 45.3% | |
Exports to sales | % | 24.8 | 20.9 | 118.7% | |
Imports to sales | % | 3.7 | 8.1 | 45.9% | |
Exports (fob) | Rs m | 3,956 | 954 | 414.7% | |
Imports (cif) | Rs m | 596 | 372 | 160.3% | |
Fx inflow | Rs m | 4,952 | 1,203 | 411.6% | |
Fx outflow | Rs m | 697 | 467 | 149.3% | |
Net fx | Rs m | 4,255 | 736 | 577.8% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 2,786 | 1,049 | 265.7% | |
From Investments | Rs m | -1,529 | -54 | 2,857.8% | |
From Financial Activity | Rs m | -941 | -1,011 | 93.0% | |
Net Cashflow | Rs m | 316 | -20 | -1,606.1% |
Indian Promoters | % | 61.4 | 74.5 | 82.4% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 3.7 | 0.6 | 616.7% | |
FIIs | % | 12.7 | 1.3 | 976.9% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 22.1 | 23.6 | 93.6% | |
Shareholders | 46,261 | 10,259 | 450.9% | ||
Pledged promoter(s) holding | % | 35.8 | 35.1 | 102.0% |
Compare DISHMAN PHARMA With: TORRENT PHARMA NATCO PHARMA CADILA HEALTHCARE PFIZER ALKEM LABORATORIES
Compare DISHMAN PHARMA With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
The market scaled new life-time highs this week but it was the bears who took control. The benchmark indices, Sensex and Nifty ended mostly flat for the week but the momentum was in favour of the bears.
Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.
For the quarter ended December 2018, PANACEA BIOTECH has posted a net profit of Rs 230 m (down 137.1% YoY). Sales on the other hand came in at Rs 1 bn (down 25.2% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.
Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.
For the quarter ended December 2018, PANACEA BIOTECH has posted a net profit of Rs 230 m (down 137.1% YoY). Sales on the other hand came in at Rs 1 bn (down 25.2% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.
More Views on NewsWere you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.
Our ace stock picker is ready to capitalise on a big growth opportunity.
The pandemic failed to thwart Richa's investing success formula for 2020.
More